Background: Clinical care for children and adults living with sickle cell disease (SCD) is often provided in the emergency department (ED). Population-based surveillance data can be used to describe the ED utilization patterns of this patient population.
INTRODUCTION
Sickle cell disease (SCD) affects 70,000-100,000 individuals in the United States. 1, 2 The acute painful vaso occlusive events that are the hallmark of SCD, along with other clinical manifestations of the disease, may result in visits to the emergency department (ED) when the events cannot be successfully managed at home or during an outpatient visit. 3 Frequency of ED visits may also be associated with factors related to the healthcare system, such as lack of access to care, few or no SCD clinical care experts located nearby, or inadequate coverage for the payment of medical services. [4] [5] [6] Between 47% and 67% of patients' Abbreviations: ED, emergency department; ICD, International Classification of Disease; PHRESH, Public Health Research, Surveillance, and Epidemiology for Hemoglobinopathies;
RuSH, Registry and Surveillance System for Hemoglobinopathies; SCD, sickle cell disease; SCDC, Sickle Cell Data Collection Program; SSN, social security number ED visits end in a discharge, termed as a treat-and-release visit; the remainder result in an inpatient admission to a hospital or other treatment facility. 7, 8 The information that is currently available about ED visits by patients with SCD is the result of analyses of data from either a single clinical institution or a consortium of institutions, or from a dataset based on a single source of administrative data (i.e., hospital discharge or Medicaid). Each type of data source has advantages and disadvantages for these types of epidemiologic studies. Clinical The analyses presented here include treat-and-release ED visits only, except where noted. Mean and median annual rates of utilization across multiple years were calculated using the number of ED visits and person years for the subgroup of interest (e.g., 10-year age group, sex).
Person years were calculated based on an entrance to the study on 
RESULTS
There were 4,636 patients with SCD identified in California during 2004-2008 who met the inclusion criteria for this study (Table 1) . SCD genotype was known for 1,624 (35%) of these patients The data from this study were compared using matching age groups to earlier published work describing ED treat-and-release utilization for SCD (Table 2) . Compared to Epstein, the California data showed similar utilization in the 20-to 30-year and 41-to 50-year age groups, but lower in the 31-to 40-year age group and higher in the oldest age group. 7 California data showed markedly higher utilization among those aged 18 and older compared to Brousseau. 8 When 2005 ED treat-and-release utilization data were compared to Shankar's prior work, results were similar. 13 The proportion of patients with an ED treat-and-release visit in 2005 was calculated across four frequency-of-visit categories: none (0 visits), low (1-3 visits), medium (4-10 visits), and high (11 or more visits) (Table 3 ). These proportions were very similar in subsequent years, with less than 2% variation across categories of utilization by year. Chisquare tests of observed (individual years) versus expected (sum of all 10 years) distribution across no, low, medium, and high utilization categories were not statistically significant, with all P values >0.8.
TA B L E 1
Description of individuals with sickle cell disease (SCD) and their treat-and-release emergency department (ED) utilization, California, 2005-
DISCUSSION
Tracking a population-based cohort of patients living with SCD in California over a 10-year period offers a unique perspective on patterns of ED utilization. While the exact number of patients living with SCD in the state is not currently known, these analyses provide information on over 70% of the total number estimated by previous studies. 1,2 Nearly half of the identified population living with SCD had one or more treat-and-release visits in any given year, and 88% had one or more (15) 42 (5) 30-39.9 (n = 630) 263 (42) 256 (41) 84 (13) 27 (4) 40-49.9 (n = 553) 254 (46) 198 (36) 65 (12) 36 (7) 50-59.9 (n = 260) 122 (47) 99 (38) 28 (11) 11 (4) 60-69.9 (n = 70) 37 (53) 29 (41) 1 (1) 3 (4) 70-79.9 (n = 24) 15 (63) Total row percentage may not equal 100, due to rounding.
TA B L E 2 Comparison of mean annual treat-and-release emergency department (ED) visits for individuals with sickle cell disease (SCD) (California, 2005-2014) to previously published SCD ED utilization reports

Previous estimates California
such visits during the 10-year period. As other research has shown, the total number of ED visits was highest among young adults. These analyses show that when normalized for person years and diminished denominator in older age groups, mean number of visits per year was high among those up to age 60 as well.
Previous studies found that 47-67% of ED visits among those with SCD were treat-and-release. 7, 8 The analyses described here yielded similar results: 66% of ED visits were treat-and-release. The dramatic rise in ED visits during the young adult period is also consistent with the trends of increased utilization during this age, which have been described by others. 6, 8 In comparison to previous publications that have reported mean annual ED treat-and-release visits ranging from as few as 1.1 visits to as many as 4.9 visits, these data show an average of 2.1 ED treat-and-release visits per year for all included patients with SCD. 7, 8, 16 Finally, while treat-and-release ED utilization is high among this group of patients with SCD overall, these data yielded a small number of individuals (3%) in any given year who were very high utilizers. In This study highlights the power and utility of a multisource longitudinal data collection effort for SCD. Individuals described here were identified using population-based surveillance methods, rather than relying on data from a small number of clinical institutions or from a single administrative dataset. This method of patient identification and tracking, along with the inclusion criteria that were employed, ensured that these analyses included patients with SCD who spanned the spectrum of disease severity. The difference in data sources and breadth of data collection may explain some of the differences between mean annual number of visits in this study and those reported by others.
For example, a study that identifies patients with SCD using ICD-9-CM codes in a single-source dataset 3, 5, 8, 11, 13, [16] [17] [18] [19] [20] [21] may include an excess number of individuals without a true SCD diagnosis, as the code could have been used to indicate a rule-out diagnosis or may be the result of miscoding. 9 Such an error would increase the total number of patients with SCD (denominator), resulting in a lower mean number of visits.
Alternatively, a study that collects information from an SCD specialty clinic or clinics may contain a greater number of patients with severe illness and consequently, greater ED utilization than the general SCD population. 4, 7, 22 There are limitations to this work. These data indicate that most identified SCD patients had at least one treat-and-release visit over the 10-year study period, and nearly half have one or more such visits in any given year. Treat-and-release ED utilization among patients with SCD is highest among young and middle-aged adults. They also show that a substantial portion of those living with this disease do not have such visits in a single year. The similarities and differences among the analyses of these data and related prior publications highlight the importance of a population-based data collection system that captures information on healthcare utilization, access to care, and health outcomes for all patients with SCD.
